ViaGenetics® began as a technology company in 2013 and has now transitioned to research and drug development.
ViaGenetics built the world’s first genomic search engine and collaboration platform.
Now, ViaGenetics is using its genomic discoveries to reveal precursor factors to diagnose, prevent, treat or cure disease.
Our genomic platform is user-friendly by design, and fosters collaboration across all users, to include clinicians with little to no genomic or bioinformatics training.
Initial Beta Test Results:
50+disease related genes discovered 80+published papers
Meet the ViaGenetics® Team
CEO & Chief Innovation Officer
Sets the strategic policy and directs the intellectual property development
Selected by the National Academy of Science as one of the leading innovators in America in 2009
Specialist in intellectual property and an expert in process and methods with well over 100 patents
Chief Learning Officer & BoD Member
Chief Learning Officer and Managing Director at Goldman Sachs
Previously VP of Corporate Leadership Development and Chief Learning Officer at General Electric, responsible for GE's renowned leadership education center at Crotonville
Served on the faculties of Ohio State University, the University of Southern California, and the University of Michigan, and was Dean of the faculty of the USC business school from 1985 to 1989
Jeff Cummings, MD, ScD
Chief Science Officer
Leads the establishment of protocols and validation of the research
Multiple Alzheimer’s awards: i) Henderson Award of the American Geriatrics Society, ii) the Research Award of the John Douglas French Alzheimer’s Research Foundation and iii) the Ronald and Nancy Reagan Research Award of the national Alzheimer’s Association
Hakon Hakonarson, M.D., Ph.D.
Chief Science Advisor
Leads the Company’s Alzheimer’s study
Dr. Hakonarson has over 20 years of experience in pioneering genomics research and genome-wide mapping and association studies
Previously directed a number of genomics and pharmacogenomics projects as vice president of Clinical Sciences and Development at deCODE Genetics, Inc. (“deCODE”)
Marni Falk, MD
Program Lead, Targeted Cancer
Executive Director of the CHOP Mitochondrial Medicine Center
PI of active NIH-funded research laboratory investigating the genetic etiologies, mechanisms, and therapies for mitochondrial diseases with over 85 publications
Cynthia M. Otto, DVM, Ph.D.
Professor within the University of Pennsylvania School of Veterinary Medicine
Current Research Interests are focused on the health, genetic and behavioral aspects of performance in detection dogs
Charlie Johnson, Ph.D.
Professor of Physics at the University of Pennsylvania
Director of Nano / Bio Interface Center
Research includes transport phenomena in nanoscale systems and hybrid nanostructures conjugated with proteins, synthetic peptides, and DNA